[go: up one dir, main page]

AR097613A1 - DOSAGE OF GIP / GLP-1 CO-ANTAGONIST PEPTIDES FOR HUMAN ADMINISTRATION - Google Patents

DOSAGE OF GIP / GLP-1 CO-ANTAGONIST PEPTIDES FOR HUMAN ADMINISTRATION

Info

Publication number
AR097613A1
AR097613A1 ARP140103371A ARP140103371A AR097613A1 AR 097613 A1 AR097613 A1 AR 097613A1 AR P140103371 A ARP140103371 A AR P140103371A AR P140103371 A ARP140103371 A AR P140103371A AR 097613 A1 AR097613 A1 AR 097613A1
Authority
AR
Argentina
Prior art keywords
single unit
unit dose
peptide
seq
amino acid
Prior art date
Application number
ARP140103371A
Other languages
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR097613A1 publication Critical patent/AR097613A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Métodos para tratar la obesidad o diabetes, así como métodos relacionados para reducir el aumento de peso o inducir la pérdida de peso, tratar hiperglucemia, o mejorar el control glucémico en humanos tratados con rangos de dosis de un péptido coantagonista GIP/GLP-1. Reivindicación 1: Una dosis unitaria única de un péptido que comprende la secuencia de aminoácidos de cualquiera de las SEC ID Nº 2 - 8 en una cantidad que oscila entre aproximadamente 0,75 mg y aproximadamente 2,5 mg, opcionalmente, caracterizada porque el péptido está presente en la dosis unitaria única con un portador o excipiente farmacéuticamente aceptable. Reivindicación 9: La dosis unitaria única de la reivindicación 1 caracterizada porque el péptido comprende la secuencia de aminoácidos de la SEC ID Nº 6. Reivindicación 13: Una dosis unitaria única de un péptido que comprende la secuencia de aminoácidos de la SEC ID Nº 2 en una cantidad que oscila entre aproximadamente 0,75 mg y aproximadamente 2,5 mg. Reivindicación 14: La dosis unitaria única de la reivindicación 13 caracterizada porque el péptido comprende la secuencia de aminoácidos de la SEC ID Nº 6. Reivindicación 17: Un kit, dispositivo o recipiente que comprende la dosis unitaria única de cualquiera de las reivindicaciones 13 a 16.Methods to treat obesity or diabetes, as well as related methods to reduce weight gain or induce weight loss, treat hyperglycemia, or improve glycemic control in humans treated with dose ranges of a GIP / GLP-1 coantagonist peptide. Claim 1: A single unit dose of a peptide comprising the amino acid sequence of any of SEQ ID NO: 2-8 in an amount ranging from about 0.75 mg to about 2.5 mg, optionally characterized in that the peptide It is present in the single unit dose with a pharmaceutically acceptable carrier or excipient. Claim 9: The single unit dose of claim 1 characterized in that the peptide comprises the amino acid sequence of SEQ ID No. 6. Claim 13: A single unit dose of a peptide comprising the amino acid sequence of SEQ ID No. 2 in an amount ranging from about 0.75 mg to about 2.5 mg. Claim 14: The single unit dose of claim 13 characterized in that the peptide comprises the amino acid sequence of SEQ ID NO. 6. Claim 17: A kit, device or container comprising the single unit dose of any of claims 13 to 16 .

ARP140103371A 2013-09-09 2014-09-10 DOSAGE OF GIP / GLP-1 CO-ANTAGONIST PEPTIDES FOR HUMAN ADMINISTRATION AR097613A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361875686P 2013-09-09 2013-09-09

Publications (1)

Publication Number Publication Date
AR097613A1 true AR097613A1 (en) 2016-04-06

Family

ID=51582537

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103371A AR097613A1 (en) 2013-09-09 2014-09-10 DOSAGE OF GIP / GLP-1 CO-ANTAGONIST PEPTIDES FOR HUMAN ADMINISTRATION

Country Status (2)

Country Link
AR (1) AR097613A1 (en)
WO (1) WO2015035419A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021093883A1 (en) * 2019-11-15 2021-05-20 江苏豪森药业集团有限公司 Dual receptor-acting agonist compounds and pharmaceutical composition thereof
MX2023000303A (en) 2020-07-22 2023-02-09 Novo Nordisk As COAGONISTS OF GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTORS SUITABLE FOR ORAL SUPPLY.
TW202330584A (en) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 Prodrugs and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2300035B1 (en) * 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
JP2013518115A (en) * 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
CA2796894A1 (en) * 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
RU2013133803A (en) * 2010-12-22 2015-01-27 Маркадиа Байотек, Инк. METHODS FOR TREATING METABOLIC DISTURBANCES AND OBESITY BY USING PEPTIDS BASED ON GLUCAGON, ACTIVE AGAINST GUIP AND GLP RECEPTORS
EA201390941A1 (en) * 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн GLUCAGON ANALOGUES, EXPERIENCING ACTIVITY ON GIP RECEPTOR
US20140051834A1 (en) * 2012-06-21 2014-02-20 Hoffmann-La Roche, Inc. Incretin Receptor Ligand Polypeptide Fc-Region Fusion Polypeptides And Conjugates With Altered Fc-Effector Function

Also Published As

Publication number Publication date
WO2015035419A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
CL2019003091A1 (en) Combination therapy.
MX2015014408A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use.
MX390627B (en) USE OF PRIDOPIDINE FOR THE TREATMENT OF FUNCTIONAL DECREASING.
MX2018011102A (en) COMBINATIONS OF LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS (LSD1) FOR USE IN THE TREATMENT OF SOLID TUMORS.
AR105816A2 (en) FUNCTIONALIZED EXENDINA-4 DERIVATIVES
SV2015005115A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
MX2020003719A (en) THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR THE TREATMENT OF CANCER.
NZ611878A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
EA201690494A1 (en) ACYLATED GLUCAGON ANALOGUES
AR099976A1 (en) DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGON RECEPTORS DERIVED FROM EXENDINA-4
AR099975A1 (en) DERIVATIVES OF EXENDINA-4 AS DUAL PEPTIDE AGONISTS OF THE GLP-1 / GLUCAGÓN RECEPTOR
MX2016002152A (en) Method for increasing expression of rna-encoded proteins.
AR124500A2 (en) INCREASED BIOAVAILABILITY OF THE DRUG IN NALTREXONE THERAPY
EA201291233A1 (en) ANALOGUE GLUACAGONA
CR20140086A (en) COMBINATION TREATMENTS FOR HEPATITIS C
JP2015517488A5 (en)
AR107890A1 (en) GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY
BR112014030404A2 (en) hgh-xten fusion protein and its use in the treatment of growth hormone deficiency
AR078224A1 (en) COMPOSITION FOR THE TREATMENT OF PROSTATE CANCER
CO2020008308A2 (en) Modified lipidated relaxin b-chain peptides and their therapeutic use
MX361778B (en) PHARMACEUTICAL COMPOSITIONS and METHODS OF TREATMENT.
CY1124812T1 (en) METHOD OF IMMUNE BOOSTING THERAPEUTIC TREATMENT OF CANCER
PE20171622A1 (en) INSULIN GLARGIN / LIXISENATIDE FIXED RATIO FORMULATION
EP3501532A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
EA201500061A1 (en) PHARMACEUTICAL COMPOSITION FOR THERAPY FOR PULMONARY FORMS OF HIGH-DISTANCE DISEASE, CAUSED BY OXYGEN FASTENGEN AND REDUCED ATMOSPHERIC PRESSURE

Legal Events

Date Code Title Description
FB Suspension of granting procedure